Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

2013868 citationsJournal Articlebronze Open Access

Authors

Sharon Walmsley · University Health Network

Antonio Antela · Complejo Hospitalario Universitario de Santiago

Nathan Clumeck · Centre Hospitalier Universitaire de Saint-Pierre

Dan Duiculescu · Spitalul Clinic Dr. Victor Babes

Andrea Eberhard · Center for HIV and Hepatogastroenterology

Félix Gutiérrez · Universitat de Miguel Hernández d'Elx

Laurent Hocqueloux

Abstract

Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine. (Funded by ViiV Healthcare; SINGLE ClinicalTrials.gov number, NCT01263015 .).

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 19, pp. 1807-1818

DOI: 10.1056/nejmoa1215541

Field-Weighted Citation Impact: 40.78